DE3855501D1 - Chinolin-derivate als antagonisten von leukotrien d 4? - Google Patents

Chinolin-derivate als antagonisten von leukotrien d 4?

Info

Publication number
DE3855501D1
DE3855501D1 DE3855501T DE3855501T DE3855501D1 DE 3855501 D1 DE3855501 D1 DE 3855501D1 DE 3855501 T DE3855501 T DE 3855501T DE 3855501 T DE3855501 T DE 3855501T DE 3855501 D1 DE3855501 D1 DE 3855501D1
Authority
DE
Germany
Prior art keywords
antagonists
leukotria
chinoline derivatives
chinoline
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3855501T
Other languages
English (en)
Other versions
DE3855501T2 (de
Inventor
Fu-Chi Huang
Robert Galemmo
Henry Campbell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhone Poulenc Rorer International Holdings Inc
Original Assignee
Rhone Poulenc Rorer International Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer International Holdings Inc filed Critical Rhone Poulenc Rorer International Holdings Inc
Application granted granted Critical
Publication of DE3855501D1 publication Critical patent/DE3855501D1/de
Publication of DE3855501T2 publication Critical patent/DE3855501T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
DE3855501T 1987-11-02 1988-11-01 Chinolin-derivate als antagonisten von leukotrien d 4? Expired - Lifetime DE3855501T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/116,597 US4920130A (en) 1987-11-02 1987-11-02 Quinoline derivatives and use thereof as antagonists of leukotriene D4
PCT/US1988/003896 WO1989004304A1 (en) 1987-11-02 1988-11-01 Quinoline derivatives as antagonists of leukotriene d4

Publications (2)

Publication Number Publication Date
DE3855501D1 true DE3855501D1 (de) 1996-10-02
DE3855501T2 DE3855501T2 (de) 1997-01-16

Family

ID=22368142

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3855501T Expired - Lifetime DE3855501T2 (de) 1987-11-02 1988-11-01 Chinolin-derivate als antagonisten von leukotrien d 4?

Country Status (8)

Country Link
US (2) US4920130A (de)
EP (1) EP0397697B1 (de)
JP (1) JPH03500890A (de)
AT (1) ATE141917T1 (de)
AU (1) AU635199B2 (de)
DE (1) DE3855501T2 (de)
MX (1) MX9203772A (de)
WO (1) WO1989004304A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017583A (en) * 1983-04-21 1991-05-21 Merck Frosst Canada, Inc. Leukotriene antagonists
US4920130A (en) * 1987-11-02 1990-04-24 Rorer Pharamceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US5051427A (en) * 1987-11-03 1991-09-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinoline derivatives as antagonists of leukotriene D4
US5204358A (en) * 1987-11-25 1993-04-20 Merck Frosst Canada, Inc. Hetaryl styryl quinolines as leukotriene inhibitors
US5104882A (en) * 1987-11-25 1992-04-14 Merck Frosst Canada, Inc. Diarylstrylquinoline diacids and pharmaceutical compositions thereof
US5232916A (en) * 1988-06-27 1993-08-03 Merck Frosst Canada, Inc. Quinoline ether alkanoic acids
US5102881A (en) * 1988-06-27 1992-04-07 Merck Frosst Canada, Inc. Quinoline ether alkanoic acids
US5214069A (en) * 1988-12-23 1993-05-25 Imperial Chemical Industries Plc Alcohol and ether derivatives
US5219881A (en) * 1988-12-23 1993-06-15 Imperial Chemical Industries Plc Cyclic ether derivatives
GB8926981D0 (en) * 1988-12-23 1990-01-17 Ici Plc Heterocyclic derivatives
GB8927287D0 (en) * 1988-12-23 1990-01-31 Ici Plc Cyclic ether derivatives
IL92620A0 (en) * 1988-12-23 1990-08-31 Ici Pharma Cycloalkane derivatives
NZ231735A (en) * 1988-12-23 1992-04-28 Ici Plc Alcohol/ether derivatives, preparation and pharmaceutical compositions thereof
US5196419A (en) * 1989-02-28 1993-03-23 Imperial Chemical Industries Plc Heterocyclic cyclic ethers
US5217977A (en) * 1989-02-28 1993-06-08 Imperial Chemical Industries Plc Heterocyclic cycloalkanes
US5202326A (en) * 1989-02-28 1993-04-13 Imperial Chemical Industries Plc Heterocyclic ethers
US5134148A (en) * 1989-02-28 1992-07-28 Imperial Chemical Industries Plc Heterocycles for use as inhibitors of leukotrienes
US5236919A (en) * 1989-02-28 1993-08-17 Imperial Chemical Industries Plc Quinoxalinyl derivatives suitable for use in leukotriene mediated disease
US4977162A (en) * 1989-07-13 1990-12-11 Rorer Pharmaceutical Corporation Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments
IE902113A1 (en) * 1989-07-18 1991-06-19 Ici Plc Diaryl ether cyclic ethers
IE64358B1 (en) * 1989-07-18 1995-07-26 Ici Plc Diaryl ether heterocycles
US5214070A (en) * 1989-07-18 1993-05-25 Imperial Chemical Industries Plc Diaryl ether cycloalkanes
EP0410661B1 (de) * 1989-07-26 1994-06-15 Imperial Chemical Industries Plc Bizyklische Derivate
PT94960A (pt) * 1989-08-11 1991-04-18 Ici Plc Processo para a preparacao de derivados de quinolina e de composicoes farmaceuticas que as contem
GB9018134D0 (en) * 1989-09-29 1990-10-03 Ici Plc Heterocyclic derivatives
GB9010394D0 (en) * 1990-05-09 1990-06-27 Ici Plc Heterocyclic compounds
US5254581A (en) * 1990-06-21 1993-10-19 Imperial Chemical Industries Plc Pyran derivatives and their use as inhibitors of 5-lipoxygenase
ATE134630T1 (de) * 1990-06-21 1996-03-15 Zeneca Ltd Bizyklische pyran-derivate und ihre verwendung als 5-lipoxygenasehemmer
AU637500B2 (en) * 1990-06-21 1993-05-27 Zeneca Limited Bicyclic heterocyclic compounds
IE911853A1 (en) * 1990-06-21 1992-01-01 Ici Plc Heterocyclene derivatives
GB9113137D0 (en) * 1990-07-13 1991-08-07 Ici Plc Thioxo heterocycles
US5266568A (en) * 1990-10-12 1993-11-30 Merck Frosst Canada, Inc. Hydroxyalkylquinoline ether acids as leukotriene antagonists
GB9025123D0 (en) * 1990-11-19 1991-01-02 Ici Plc Nitrogen compounds
IE913866A1 (en) * 1990-11-28 1992-06-03 Ici Plc Aryl derivatives
US5272173A (en) * 1990-11-28 1993-12-21 Imperial Chemical Industries Plc 5-lipoxygenase inhibitors
IE914005A1 (en) * 1990-12-14 1992-06-17 Zeneca Ltd Novel intermediates
CA2058254A1 (en) * 1991-01-15 1992-07-16 John Francis Kingston Benzodioxole derivatives
AU645159B2 (en) * 1991-01-17 1994-01-06 Ici Pharma Sulphonamide derivatives
US5258399A (en) * 1991-01-17 1993-11-02 Imperial Chemical Industries Plc Sulphonamide derivatives
GB9102804D0 (en) * 1991-02-11 1991-03-27 Ici Plc Heterocyclic derivatives
EP0505122A1 (de) * 1991-03-21 1992-09-23 Zeneca Limited Alpha, Alpha-Dialkylbenzylderivate
US5157040A (en) * 1991-04-05 1992-10-20 Merck & Co., Inc. Substituted quinolines as angiotensin ii antagonists
AU1625192A (en) * 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
GB9113628D0 (en) * 1991-06-25 1991-08-14 Ici Plc Heterocyclic derivatives
GB9113626D0 (en) * 1991-06-25 1991-08-14 Ici Plc Heterocyclic compounds
GB9121727D0 (en) * 1991-10-14 1991-11-27 Ici Plc Heterocyclic compounds
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
US5731324A (en) * 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
US6137002A (en) 1993-07-22 2000-10-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
US6448269B1 (en) 1993-07-22 2002-09-10 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
US5556990A (en) * 1994-12-16 1996-09-17 Rhone-Poulenc Rorer Pharmaceuticals Inc. Polyarylcarbamoylaza- and -carbamoylalkanedioic acids
ES2117551B1 (es) * 1995-12-29 1999-04-01 Menarini Lab Quinolinas naftalenicas con accion antagonista de los leucotrienos, procedimiento para su preparacion y utilizacion de las mismas.
JP3895404B2 (ja) * 1996-05-17 2007-03-22 興和株式会社 カルコン誘導体及びこれを含有する医薬
JP2001514660A (ja) * 1997-03-13 2001-09-11 メルク エンド カンパニー インコーポレーテッド キノリンロイコトリエン拮抗薬
US5952347A (en) * 1997-03-13 1999-09-14 Merck & Co., Inc. Quinoline leukotriene antagonists
WO1999020275A1 (en) * 1997-10-17 1999-04-29 Aventis Pharmaceuticals Products Inc. Therapeutic uses of quinoline derivatives
ES2533065T3 (es) 2010-07-09 2015-04-07 Pfizer Limited Bencenosulfonamidas útiles como inhibidores de los canales de sodio
WO2012007877A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
ES2526981T3 (es) 2010-07-12 2015-01-19 Pfizer Limited N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
CA2801032A1 (en) 2010-07-12 2012-01-19 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
CA2804877A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282230A (en) * 1979-11-15 1981-08-04 E. R. Squibb & Sons, Inc. Imidazolylethoxy derivatives of quinoline-2- or 4-methanols, antimicrobial compositions containing them and method for treating bacterial or fungal infections with them
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4661499A (en) * 1985-06-18 1987-04-28 Merck Frosst Canada, Inc. 2-[(substituted)-phenoxymethyl]quinolines
IE861607L (en) * 1985-06-18 1986-12-18 Bunce Roger A 2-substituted quinolines
IE59889B1 (en) * 1986-02-14 1994-04-20 Merck Frosst Canada Inc 2-substituted quinoline dioic acids
AU612569B2 (en) * 1986-03-13 1991-07-18 Rorer International (Overseas) Inc. Quinolinyl ether or thioether tetrazoles as agents for the treatment of hypersensitive ailments
US4769461A (en) * 1986-09-16 1988-09-06 American Home Products Corporation Quinolinyl benzene hydroxamic acids as anti-inflammatory/antiallergic agents
US4920133A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920130A (en) * 1987-11-02 1990-04-24 Rorer Pharamceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4920131A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US4918081A (en) * 1988-06-20 1990-04-17 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene d4
US4977162A (en) * 1989-07-13 1990-12-11 Rorer Pharmaceutical Corporation Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments

Also Published As

Publication number Publication date
EP0397697A4 (en) 1991-07-03
DE3855501T2 (de) 1997-01-16
AU2911489A (en) 1989-06-01
EP0397697A1 (de) 1990-11-22
US5028615A (en) 1991-07-02
ATE141917T1 (de) 1996-09-15
MX9203772A (es) 1992-07-01
JPH03500890A (ja) 1991-02-28
US4920130A (en) 1990-04-24
AU635199B2 (en) 1993-03-18
EP0397697B1 (de) 1996-08-28
WO1989004304A1 (en) 1989-05-18

Similar Documents

Publication Publication Date Title
DE3855501T2 (de) Chinolin-derivate als antagonisten von leukotrien d 4?
DE69200685D1 (de) Benzocyclobutyl- oder Indanyl-Alkyl-Amino-Alkyl substituierte 3-Benzazepin-2-ones, verwendbar in der Behandlung von kardiovaskularen Krankheiten.
FI895213A0 (fi) Foereningar avsedda foer vaord av alzheimers sjukdom.
ATE126232T1 (de) Neue derivate von a-nor-3-carboxysteroiden.
DE69232665D1 (de) Neue 4-arylpiperazine und 4-arylpiperidine
FR10C0016I2 (fr) Procedes et compositions s'appliquant au traitement de la glomerulonephrite
FI931370A0 (fi) Kvaeve innehaollande analoger av icke-aromatiska heterocykliska foereningar med en fusionerad ring
DE3878866T2 (de) 3-indolpyruvsaeure-derivate und deren verwendung als arznemittel.
DE3783105T2 (de) Chinolinylaether tetrazole als mittel zur behandlung von hyperempfindlichen krankheiten.
DE3650647D1 (de) Arzneimittel zur Behandlung von Anxietas
NO891703L (no) Farmasoeytiske sammensetninger for behandling av psoriasis.
DK496687D0 (da) Anvendelse af medetomidin til fremstilling af laegemiddel til brug ved behandling af angstsygdomme
ATE113591T1 (de) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva.
FI844645A0 (fi) 1,7-difenyl-3-metylaza-7-cyan-8 -metyl-nonan foer anvaendning vid bekaempning av sjukdomar.
ATE210645T1 (de) Pyridiniumderivate und ihre verwendung zur bestimmung von bindegewebeerkrankungen bei menschen und tieren
ATE86983T1 (de) Acyl-derivate von hydroxy-pyrimidinen.
ES2089511T3 (es) Dihidroquinolina antagonistas de nmda.
ATE82124T1 (de) Anwendung von n-(2-(diaethylamino)aethyl>-2-methoxy-4((1-h-4,5ihydro-2-imidazolyl)amino>-5- chlorobenzamid als anxiolytisches und antipsychotisches mittel.
SE8201308D0 (sv) Alkylendiaminderivat och forfarande for framstellning derav
ATE72112T1 (de) Verwendung von 1-benzyl-amino-alkylpyrrolidinonen als antidepressiva.
ATE86493T1 (de) Gebrauch von gramineenextrakten als arzneimittel.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition